EMA Authorised: Wainzua (eplontersen sodium) — AstraZeneca AB

View source ↗

Summary

The European Medicines Agency authorised Wainzua (eplontersen sodium) from AstraZeneca AB for familial amyloid polyneuropathy.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Familial Amyloid Polyneuropathy

Drugs mentioned

• Wainzua (eplontersen)

Snippet

Status: Authorised. Therapeutic area: Amyloid Neuropathies, Familial. MAH: AstraZeneca AB. Decision date: 26/01/2026